Class specific antibody response to gonococcal infection

A MIETTINEN, * KATI HAKKARAINEN, * P GRÖNROOS, † P HEINONEN, †† K TEISALA, † R AINE, †‖ I SILLANTAKA, ** K SAARENMAA, ** M LEHTINEN, * R PUNNONEN, †† J PAAVONEN †

From the Departments of *Biomedical and †Clinical Sciences, University of Tampere, the Departments of ††Clinical Microbiology, †‖Obstetrics and Gynaecology, and †‡Pathology, University Central Hospital, Tampere, and the **Venereal Disease Clinic, Medical Centre of the City of Tampere, Finland

SUMMARY An enzyme immunoassay was used to determine IgM, IgG, and IgA antibodies to gonococcal pili in 68 patients with uncomplicated gonorrhoea, 35 women with pelvic inflammatory disease, and in 115 normal controls. A clear difference in response rate in all three antibody classes between patients with gonorrhoea and healthy controls was evident. Among women with gonorrhoea, the magnitude of antibody response was higher than among men with gonorrhoea, especially in the IgM class. No major differences were found in the overall distribution of serological findings between women with uncomplicated gonorrhoea and those with gonococcal pelvic inflammatory disease. Among this last group, however, high IgM antibody levels in acute phase sera were significantly associated with the isolation of Neisseria gonorrhoeae in the upper genital tract.

Gonococcal pili are filamentous structures present on the surface of the colonial variants T1 and T2 of Neisseria gonorrhoeae: they constitute a virulence factor for the organism. Pili are considered to be specific gonococcal antigens, and several serological tests using gonococcal pili as antigen have been described, including indirect haemagglutination, radioimmunoassay, and enzyme immunoassay (EIA). Regardless of the method used, however, the diagnostic value of total serum antibody determinations is limited by the persistence of antibody from previous infections. Moreover, the time course of the class specific antibody responses in uncomplicated and complicated gonorrhoea has not been clearly defined. In the present study we applied a four layer modification of the EIA for the determination of gonococcal pilus antibodies and investigated the distribution of IgM, IgG, and IgA antibodies in patients with uncomplicated gonorrhoea and patients with pelvic inflammatory disease (PID).

Material and methods

Sera were obtained from 68 patients with gonorrhoea (39 men and 29 women) attending the Venereal Disease Clinic in Tampere between February and April 1986. Gonococcal infection was diagnosed on the basis of a positive culture of N gonorrhoeae from the urethra in men and from the urethra or cervix in women. None of the patients admitted a history of gonorrhoea.

Sera were also obtained from 35 women with acute PID seen consecutively at the Department of Obstetrics and Gynaecology, University Central Hospital, Tampere. All were admitted to hospital and underwent laparoscopy and endometrial biopsy. They were evaluated as previously described in detail. Specimens for microbial cultures were obtained from the cervix, endometrium, fallopian tubes and rectum and handled as described previously.

Sera were obtained from 115 apparently healthy female blood donors who served as normal controls. They were not examined or questioned regarding gonorrhoea.

Strain 6650 of N gonorrhoeae was used. The antigenicity of pili from this strain has been previously characterised. The pili were purified by precipitation with ammonium sulphate as described by Siegel et al. The purity of the pili preparation was assessed by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE).

EIA METHOD FOR DETERMINATION OF ANTIBODIES TO GONOCOCCAL PILUS ANTIGEN

Antibodies to gonococcal pilus antigen were assayed with a four layer modification of EIA. Microtitre plates (M129A, flat bottom, Dynatech Laboratories,group.bmj.com on June 21, 2017 - Published by http://jcp.bmj.com/Downloaded from
Antibody response to gonococcal infection

Alexandria, Virginia) were sensitised with 150 μl (per well) of the pilus antigen diluted 1/2000 (0.5 μg/ml) in phosphate buffered saline (PBS) (pH 7-2), incubated overnight at 37°C, and washed with PBS, pH 7-2, containing 0-5% (vol/vol) Tween 20. The samples were diluted 1/100 in PBS containing 0-05% (vol/vol) Tween 20, 5% (vol/vol) horse serum, and sodium chloride (final concentration, 0-5M). They were then incubated in duplicate in 100 μl volumes per well for 90 minutes at 37°C. After washing heavy chain-specific anti-human immunoglobulins of rabbit origin (Dako, Copenhagen, Denmark), 100 μl per well, were incubated for 45 minutes at 37°C. The dilutions were 1/4000 for anti-gamma, 1/2000 for anti-alpha, and 1/2000 for anti-mu. Finally, after washing, alkaline phosphatase-conjugated anti-rabbit immunoglobulins of swine origin (Orion Diagnostica, Helsinki, Finland), diluted 1/100 in the PBS diluent were added, 100 μl per well, and incubated for three hours at 37°C. After washing, 100 μl (per well) of p-nitrophenylphosphate substrate (Sigma, St Louis, Missouri; 1 mg/ml) diluted in diethanolamine-MgCl2 buffer (pH 10-0) was incubated for 30 minutes at 37°C and the reaction stopped by the addition of 0-3M NaOH. The colour reactions were recorded with a Titertek Multiscan spectrophotometer (Eflab Ltd, Helsinki, Finland). For quantitation of antibody activity, positive and negative reference sera were included in each test. Antibody levels were expressed in arbitrary units (EIA units; EIU), which were determined according to the formula:

\[
\text{Antibody level}_{\text{sample}} = \frac{\text{Optical density}_{\text{sample}} - \text{Optical density}_{\text{negative control}}}{\text{Optical density}_{\text{positive control}} - \text{Optical density}_{\text{negative control}}} \times 100 \text{ EIU}
\]

The optical density was measured at a wavelength of 405 nm. The cut off point for clinically important antibody levels was determined as the mean of the control population + 3 SD in IgM and IgG assays and mean + 2 SD in IgA assays, where the overall antibody levels were substantially lower.

The χ² test and Fisher’s exact test, where appropriate, were used for analysis of the contingency tables and Student’s t test was used for comparison of the means. The sensitivity of the assay was defined as the percentage of culture positive patients who were seropositive, while specificity was defined as the percentage of normal controls who were seronegative.

Results

PILUS ANTIBODIES IN PATIENTS WITH UNCOMPLICATED GONORRHOEA

In all immunoglobulin classes significantly higher percentages of positive sera and significantly higher mean antibody levels were observed among both men and women with current gonococcal infection than among normal controls, the difference being most striking for IgM (table, figs 1–3). With a specificity of 98% in the IgM assay, a sensitivity of 13% and 48% was reached in men and women in the acute phase, respectively. Specificity was calculated on the assumption that all positive test results obtained for normal controls were false positive results.

Among the patients initially negative for IgM antibodies, four (12%) of the men but none of the women gave a positive IgM result when tested two weeks later. The corresponding figures for the men and women initially negative for IgG were 15 (33%) and five (24%), respectively, and for the men and women initially negative for IgA, four (11%) and two (11%), respectively.

The percentages of IgM and IgA positive sera were significantly higher among women than among men (table). Similarly, mean serum concentrations of gonococcal IgM, IgG, and IgA antibodies were significantly higher in women than in men (table).

Table  Incidence of significant levels (EIU) of IgM, IgG, and IgA antibodies to gonococcal pilus antigen in sera from 115 healthy female blood donors, 68 patients with uncomplicated gonorrhoea, and 35 patients with PID

<table>
<thead>
<tr>
<th>Sample</th>
<th>Men (n = 39)</th>
<th>Women (n = 29)</th>
<th>Isolated (n = 10)</th>
<th>Not isolated (n = 25)</th>
</tr>
</thead>
<tbody>
<tr>
<td>IgM</td>
<td>2(2)</td>
<td>5(13)</td>
<td>p &lt; 0.01</td>
<td>5(50)††</td>
</tr>
<tr>
<td>IgG</td>
<td>4(3)</td>
<td>6(15)</td>
<td>8(28)</td>
<td>4(40)††</td>
</tr>
<tr>
<td>IgA</td>
<td>2(2)</td>
<td>3(8)</td>
<td>11(38)†</td>
<td>3(30)‡</td>
</tr>
<tr>
<td>Mean (SD) level:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IgM</td>
<td>10(11)</td>
<td>20(19)</td>
<td>49(33)*</td>
<td>50(30)††</td>
</tr>
<tr>
<td>IgG</td>
<td>10(17)</td>
<td>20(27)</td>
<td>43(45)*</td>
<td>47(32)††</td>
</tr>
<tr>
<td>IgA</td>
<td>4(16)</td>
<td>13(12)</td>
<td>34(30)*</td>
<td>28(15)††</td>
</tr>
</tbody>
</table>

Significance of differences between men and women with uncomplicated gonorrhoea: *p < 0.001; †p < 0.01; ‡p < 0.05.
Significance of differences between PID patients with and those without N gonorrhoeae: ††p < 0.001; ‡‡p < 0.01; ‡‡‡p < 0.05.
PILUS ANTIBODIES IN PATIENTS WITH PID

Of the 35 women with PID, cervical gonorrhoea was diagnosed in 10 (29%). *N. gonorrhoeae* was also isolated from the fallopian tubes of one patient, from the fallopian tubes and endometrium of one patient, and from the endometrium of two patients. Six patients also harboured *N. gonorrhoeae* in the rectum.

Significantly higher percentages of positive sera as well as significantly higher mean antibody levels were observed among patients with gonococcal PID than among those with non-gonococcal PID, the difference again being most striking for IgM (table). In contrast, no major differences were observed in the overall distribution of serological findings between women with gonococcal PID and those with uncomplicated gonococcal infection. Levels of IgM antibody were, however, related to the extent of gonococcal infection, so that all of the four patients with *N. gonorrhoeae* isolated from either fallopian tubes or endometrium, or both sites, had significant (by definition) IgM levels, compared with only one of the six patients in whom *N. gonorrhoeae* was recovered from the cervix and rectum but not from the upper genital tract (*p* = 0.024, Fisher's exact test) (fig 1). Such high IgM levels were not observed among the 25 women with non-gonococcal PID nor among normal controls. A similar but less clear correlation was found for IgA levels (fig 3); the distribution of IgG antibody was not related to the site of isolation of *N. gonorrhoeae*.

None of the patients with gonococcal PID negative for IgM antibodies in the acute phase yielded a positive result when examined two to four weeks later. In contrast, one of the seven patients initially negative for IgG antibodies, and two of the six patients initially negative for IgA antibodies, gave a positive result in the convalescent phase serum sample.

Discussion

This report describes the determination of class specific antibody response to gonococcal pili in human
Antibody response to gonococcal infection

![Graph showing IgA antibody levels in sera from healthy female blood donors and women with gonococcal infections.](image)

Fig 3  Distribution of IgA antibody levels to gonococcal pilus antigen in sera from (1) 115 healthy female blood donors; (2a) 39 men with uncomplicated gonorrhoea; (2b) 29 women with uncomplicated gonorrhoea; (3a) 10 women with gonococcal PID (PID); and (3b) 25 women with non-gonococcal PID. The anatomic sites of the isolation of N gonorrhoeae among women with PID are indicated by C = cervix, E = endometrium, T = fallopian tubes, and R = rectum. Vertical bars denote mean levels ± 1SD.

In all immunoglobulin classes significantly higher mean antibody activity and a higher percentage of positive sera were found in men and women with gonorrhoea than in controls. The determination of IgM antibodies most effectively discriminated between patients with gonorrhoea and healthy controls. A clinically important level of anti-gonococcal IgM was shown in (13%) of infected men and in (48–50%) of infected women in the acute phase compared with (0–2%) of non-infected patients with PID and healthy controls. An IgM response in the early phase of gonococcal infection has also been shown to occur in patients with uncomplicated gonorrhoea by McMillan et al., who used an immunofluorescence technique (IFAT) with whole cell antigen. In contrast, a predominance of IgG antibodies even early in the disease has been suggested in studies with IFAT using the heat labile surface antigens, and with EIA using the envelope antigen of N gonorrhoeae. It is likely that the different antigens used account for this discrepancy.

Women with gonococcal PID showed significantly higher antibody activity than women with non-gonococcal PID. Altogether, nine of the 10 patients with gonococcal PID had a clinically important level of IgM, IgG, or IgA antibodies compared with only six (20%) of 25 patients with non-gonococcal PID. The overall percentage of seropositive cases was thus higher than that previously reported with radioimmunoassay (RIA) and indirect haemagglutination pilus antigen tests by Märdh et al., and the same as reported with pilus RIA by Eschenbach et al. Moreover, unlike the 25 cases of non-gonococcal PID in this study, all women with PID and N gonorrhoeae isolated from the upper genital tract had high IgM activity, suggesting that in the acute phase of the disease IgM antibody activity reflects more clearly than IgG or IgA antibody activity the extent of gonococcal infection.

It has been estimated that almost half of the women with symptomatic or asymptomatic gonorrhoea develop upper genital tract infection. In agreement with this, of 14 (48%) of 29 women in the current study, who had N gonorrhoeae in the cervix but did not have upper genital tract symptoms or signs, showed a high IgM antibody levels as did those patients with confirmed PID in whom N gonorrhoeae was found in the upper genital tract. The high antibody activity might reflect a subclinical PID in such cases. Confirmation of this calls for laparoscopy and endometrial sampling among asymptomatic women with positive cervical cultures for N gonorrhoeae.

The gonococcal pili used here were from a single strain (6650 of N gonorrhoeae). The failure in this study to show an antibody response in half of uncomplicated gonococcal infections could have been due partly to the antigenic heterogeneity of the gonococcal pili, but also to the testing of patients with infections of varying severity. Because of the relatively low overall response rate, the test obviously cannot be regarded as an effective diagnostic tool in its own right in gonorrhoea. The observed sex difference in antibody response and the uniform IgM response among patients with PID in whom N gonorrhoeae was detected in the upper genital tract suggest, however, that the determination of antibody response can be used as an indicator of the extent of gonococcal infection.

This study was supported in part by a grant (7939/304/83) from the Academy of Finland.

We thank Drs Karin Reimann and Inga Lind, Statens Seruminstitut, Neisseria Department, Copenhagen, Denmark, for providing the N gonorrhoeae strain 6650.
References


Requests for reprints: Dr Ari Miettinen, Department of Biomedical Sciences, University of Tampere, Box 607, SF-33101 Tampere, Finland.
Class specific antibody response to gonococcal infection.

A Miettinen, K Hakkarainen, P Grönroos, P Heinonen, K Teisala, R Aine, I Sillantaka, K Saarenmaa, M Lehtinen and R Punnonen

*J Clin Pathol* 1989 42: 72-76
doi: 10.1136/jcp.42.1.72

Updated information and services can be found at:
[http://jcp.bmj.com/content/42/1/72](http://jcp.bmj.com/content/42/1/72)

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
[http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to:
[http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to:
[http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)